What is nference?
Founded in 2013 and headquartered in Cambridge, Massachusetts, nference is dedicated to building a comprehensive software platform that synthesizes the vast and often siloed biomedical knowledge. The company leverages state-of-the-art neural networks to perform real-time, automated insight extraction. By triangulating unstructured and structured information from biomedical literature, large-scale molecular data, and real-world datasets, nference aims to accelerate biomedical research and discovery. The company's approach is designed to address the exponential growth of data in the life sciences sector, providing a unified view for researchers and organizations.
How much funding has nference raised?
nference has raised a total of $131M across 3 funding rounds:
Series A
$11M
Series B
$60M
Series C
$60M
Series A (2018): $11M with participation from Matrix Capital Management and Matrix Partners
Series B (2020): $60M led by Mayo Clinic
Series C (2020): $60M supported by Matrix Capital Management Company, L.P., Mayo Clinic Ventures, Matrix Partners, and NTTVC
Key Investors in nference
Matrix Partners
Matrix Partners is an award-winning firm specializing in pet product strategy, advertising, and public relations, with a history of creating successful marketing campaigns for consumer and pet product brands since 1987.
Mayo Clinic
Mayo Clinic is a global nonprofit healthcare organization founded in 1864, renowned for its integrated clinical practice, education, and medical research, operating internationally and offering comprehensive medical services.
NTTVC
Undisclosed investor participating in the funding round.
What's next for nference?
With its substantial enterprise-level funding, nference is poised for accelerated growth and further development of its AI-driven biomedical knowledge platform. The recent strategic investment suggests a focus on expanding its technological capabilities, enhancing its data integration processes, and potentially broadening its market reach within the pharmaceutical, biotechnology, and healthcare industries. This capital infusion will likely support nference's efforts to deepen its analytical insights and solidify its position as a leader in biomedical data synthesis and knowledge extraction, driving innovation in drug discovery and personalized medicine.
See full nference company page
